Chromocell Therapeutics (CHRO) Competitors $1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CHRO vs. RANI, RNTX, CLNN, KALA, OKUR, KZR, BDRX, ESLA, MAAQ, and OVIDShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Rani Therapeutics (RANI), Rein Therapeutics (RNTX), Clene (CLNN), KALA BIO (KALA), OnKure Therapeutics (OKUR), Kezar Life Sciences (KZR), Biodexa Pharmaceuticals (BDRX), Estrella Immunopharma (ESLA), Mana Capital Acquisition (MAAQ), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Its Competitors Rani Therapeutics Rein Therapeutics Clene KALA BIO OnKure Therapeutics Kezar Life Sciences Biodexa Pharmaceuticals Estrella Immunopharma Mana Capital Acquisition Ovid Therapeutics Chromocell Therapeutics (NYSE:CHRO) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Which has more volatility and risk, CHRO or RANI? Chromocell Therapeutics has a beta of 3.63, indicating that its share price is 263% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Do analysts prefer CHRO or RANI? Rani Therapeutics has a consensus target price of $7.33, indicating a potential upside of 1,688.62%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of CHRO or RANI? 78.0% of Chromocell Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 16.4% of Chromocell Therapeutics shares are owned by insiders. Comparatively, 45.1% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CHRO or RANI more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Rani Therapeutics N/A -1,258.76%-80.52% Does the media prefer CHRO or RANI? In the previous week, Rani Therapeutics had 6 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 6 mentions for Rani Therapeutics and 0 mentions for Chromocell Therapeutics. Rani Therapeutics' average media sentiment score of 0.65 beat Chromocell Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Chromocell Therapeutics Neutral Rani Therapeutics Positive Which has preferable valuation and earnings, CHRO or RANI? Chromocell Therapeutics has higher earnings, but lower revenue than Rani Therapeutics. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08Rani Therapeutics$1.03M25.16-$30.02M-$0.99-0.41 SummaryRani Therapeutics beats Chromocell Therapeutics on 10 of the 14 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$8.69M$269.90M$5.51B$20.61BDividend YieldN/AN/A4.25%3.68%P/E Ratio-1.08N/A28.1227.27Price / SalesN/A431.06439.4667.19Price / CashN/A22.4435.5321.88Price / Book-0.819.708.234.60Net Income-$7.38M-$110.10M$3.23B$995.22M7 Day PerformanceN/A-4.84%-0.52%-1.55%1 Month Performance-89.26%11.18%6.71%4.38%1 Year Performance-88.55%20.43%27.10%8.12% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.34+6.3%N/A-88.7%$8.69MN/A-1.084Gap UpHigh Trading VolumeRANIRani Therapeutics2.1277 of 5 stars$0.60+12.1%$7.33+1,119.4%-89.6%$34.57M$1.20M-0.61110RNTXRein TherapeuticsN/A$1.55+0.6%N/AN/A$34.33MN/A-0.549CLNNClene3.4621 of 5 stars$3.80-1.8%$40.00+952.6%-23.1%$34.12M$340K-0.94100KALAKALA BIO3.917 of 5 stars$5.16-2.3%$13.50+161.6%-23.8%$33.28M$3.89M-0.6330OKUROnKure Therapeutics3.5331 of 5 stars$2.46+2.9%$32.33+1,214.4%N/A$33.24MN/A-0.47N/ANews CoverageKZRKezar Life Sciences4.1435 of 5 stars$4.53-0.4%$39.50+772.0%-30.8%$33.11M$7M-0.4260News CoverageAnalyst ForecastBDRXBiodexa Pharmaceuticals0.2139 of 5 stars$0.87+0.6%N/AN/A$31.83M$470K0.0020Gap DownESLAEstrella Immunopharma3.2935 of 5 stars$0.87-1.2%$16.00+1,736.1%-42.1%$31.52MN/A-3.35N/AMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+657.3%$30.88MN/A0.001OVIDOvid Therapeutics4.7295 of 5 stars$0.43+15.0%$3.13+626.7%-62.5%$30.58M$570K-1.2360Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies Rani Therapeutics Competitors Rein Therapeutics Competitors Clene Competitors KALA BIO Competitors OnKure Therapeutics Competitors Kezar Life Sciences Competitors Biodexa Pharmaceuticals Competitors Estrella Immunopharma Competitors Mana Capital Acquisition Competitors Ovid Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRO Stock Alerts